Phase 2, Phase 3 Recruiting Academic/Other
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Sponsor: NRG Oncology
NCT ID: NCT05174169
Sites in Virginia: - Kaiser Permanente-Burke Medical Center — Burke, Virginia
- Cancer Specialists of Tidewater Limited — Chesapeake, Virginia
- Peninsula Cancer Institute-Gloucester — Gloucester, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
- Kaiser Permanente Tysons Corner Medical Center — McLean, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Virginia: - Virginia Cancer Specialists, PC — Arlington, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Blacksburg, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Low Moor, Virginia
- Virginia Cancer Specialists, PC — Manassas, Virginia
Phase 3 Recruiting Industry
This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participa…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT05253651
Sites in Virginia: - Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care — Blacksburg, Virginia
- Oncology & Hematology Associates of Southwest Virginia — Low Moor, Virginia
- Oncology & Hematology Associates of Southwest Virginia Inc dba Blue Ridge Cancer Care — Roanoke, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care — Salem, Virginia
- Oncology & Hematology Associates of Southwest Virginia — Wytheville, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxalipl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06662786
Sites in Virginia: - Virginia Cancer Specialists — Arlington, Virginia
- Inova Schar Cancer Institute Dept of Fairfax Hospital — Fairfax, Virginia
- Richmond VA Medical Center — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fl…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06750094
Sites in Virginia: - Virginia Cancer Specialists — Arlington, Virginia
- Richmond VA Medical Center — Richmond, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instab…
Sponsor: GlaxoSmithKline
NCT ID: NCT05855200
Sites in Virginia: - GSK Investigational Site — Richmond, Virginia
Phase 3 Recruiting Industry
This study aims to address the unmet medical need of participants with metastatic colorectal cancer (mCRC) who have previously been treated with irinotecan, oxaliplatin, a fluoropyrimidine, and bevacizumab, by demonstrating an overall surv…
Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07549412
Sites in Virginia: - Virginia Oncology Associates — Newport News, Virginia
- Blue Ridge Cancer Care - 300202915 — Roanoke, Virginia
Phase 2 Recruiting Academic/Other
This phase III trial compares the addition of total ablative therapy to the usual systemic therapy versus the usual systemic therapy alone in treating patients with advanced colorectal cancer that has spread to up to 4 body sites (limited …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05673148
Sites in Virginia: - Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Virginia: - Local Institution - 2137 — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…
Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
Phase 2 Recruiting Industry
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients. Patients will be enrolled into two cohorts 1) patients with newl…
Sponsor: Endevica Bio
NCT ID: NCT06937177
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Academic/Other
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …
Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ …
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06695845
Sites in Virginia: - Blue Ridge Cancer Care — Roanoke, Virginia
Phase 2 Recruiting Industry
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combin…
Sponsor: AbbVie
NCT ID: NCT06820463
Sites in Virginia: - Virginia Cancer Specialists - Fairfax /ID# 271351 — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …
Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors. GEJ is where the food pipe (esophagus) joins the stomach…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07488676
Sites in Virginia: - Inova Schar Cancer Institute Clinical Trials — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Virginia: - Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 0295) — Roanoke, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.
Sponsor: Verastem, Inc.
NCT ID: NCT07020221
Sites in Virginia: - University of Virginia — Charlottesville, Virginia
- Virginia Cancer Specialists — Fairfax, Virginia
Phase 2 Recruiting Network
The NSABP FC-13 study is being done to determine if using immunotherapies alone or in combination with other drugs will delay or prevent colorectal cancer from coming back in patients with colorectal cancer who are ctDNA-positive after the…
Sponsor: NSABP Foundation Inc
NCT ID: NCT07058012
Sites in Virginia: - University of Virginia Health — Charlottesville, Virginia
- Bon Secours St. Francis Medical Center — Midlothian, Virginia
- Virginia Commonwealth University - Massey — Richmond, Virginia